SCHEMBL5154931

SCHEMBL5154931

O=C(O)N1CCN(CC(O)c2ccc(F)c(Cl)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.52
HTR7 P34969 1/20 0.52
KDM4E B2RXH2 4/20 0.45
HTT P42858 1/20 0.45
ADRB2 P07550 3/20 0.45
ADRB1 P08588 3/20 0.45
ADRB3 P13945 3/20 0.45
ADRA1D P25100 3/20 0.45
ADRA1A P35348 3/20 0.45
ADRA1B P35368 3/20 0.45
IGF1R P08069 5/20 0.44
ALDH1A1 P00352 2/20 0.43
TSHR P16473 3/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
GMNN O75496 1/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
ALOX15 P16050 1/20 0.41
NFKB1 P19838 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5157605 0.83 CYP3A4 (0.47) HTR1AHTR7KDM4EHTTADRB2
SCHEMBL4874915 0.77 TACR1 (0.39) MAPT
SCHEMBL21618404 0.76 FAAH (0.53) KDM4EHTTALDH1A1TSHR
SCHEMBL14676953 0.71 DPP4 (0.47) MAPT
SCHEMBL5237104 0.71 ADAMTS5 (0.52) HTTALDH1A1MAPTTP53
SCHEMBL16240334 0.70 GRIN2B (0.56) HTR1AKDM4EALDH1A1TSHRGAA
SCHEMBL12497875 0.70 SLC6A2 (0.49) KDM4EADRB2ADRB1ADRB3TSHR
SCHEMBL3242213 0.70 HTR2A (0.55) HTR1AHTR7KDM4EHTTADRA1D
SCHEMBL4971090 0.69 DPP4 (0.44) ALDH1A1MAPT
SCHEMBL4971082 0.69 DPP4 (0.44) ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070185127-A1 2-(Arylalkoxy)-1-phenylethylamine derivatives as nk1 antagonist and serotonin reuptake inhibitors ASTRAZENECA AB (SE) 2007-08-09 US disclosed
EP-1740552-A1 2- ( ARYLALKOXY ) -1- PHENYLETHYLAMINE DERIVATIVES AS NK1 ANTAGONIST AND SEROTONIN REUPTAKE INHIBITORS AstraZeneca AB (SE) 2007-01-10 EP disclosed
WO-2005100324-A1 2- ( ARYLALKOXY ) -1- PHENYLETHYLAMINE DERIVATIVES AS NK1 ANTAGONIST AND SEROTONIN REUPTAKE INHIBITORS ASTRAZENECA AB (SE) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185127-A1 2-(Arylalkoxy)-1-phenylethylamine derivatives as nk1 antagonist and serotonin reuptake inhibitors HTR1A, TPH1, HTR2A HTR1A 1/4885HTR7 22/4885KDM4E 1962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.